Showing results (11-20 of 76) with videos related to
Sort By:
Pageof 8
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 22, 2013
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusHarold BaysCurrent Atherosclerosis Reports|March 25, 2014
Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradoxHarold BaysThe American Journal of Cardiology|June 14, 2008
Safety of niacin and simvastatin combination therapyHarold BaysAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Pharmacotherapy of obesity: currently marketed and upcoming agentsHarold Bays, Carlos DujovneCurrent Medical Research and Opinion|September 3, 2015
Adiposopathy and epigenetics: an introduction to obesity as a transgenerational diseaseHarold Bays, Wendy ScintaExpert Opinion on Investigational Drugs|September 13, 2002
Anti-obesity drug developmentHarold Bays, Carlos DujovneExpert Opinion on Pharmacotherapy|May 13, 2003
Colesevelam HCl: a non-systemic lipid-altering drugHarold Bays, Carlos DujovneVascular Health and Risk Management|December 15, 2007
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factorsHarold Bays, Peter H JonesSouthern Medical Journal|March 13, 2009
Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapyTara L Dall, Harold BaysCurrent Atherosclerosis Reports|March 3, 2006
Adiposopathy is a more rational treatment target for metabolic disease than obesity aloneHarold Bays, Carlos A DujovnePageof 8